Filing Details
- Accession Number:
- 0001104659-24-117942
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-13 21:04:32
- Reporting Period:
- 2024-11-11
- Accepted Time:
- 2024-11-13 21:04:32
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1649904 | Rhythm Pharmaceuticals Inc. | RYTM | Pharmaceutical Preparations (2834) | 462159271 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1801372 | Kayden Jennifer Lee | C/O Rhythm Pharmaceuticals, Inc. 222 Berkeley Street, 12Th Floor Boston MA 02116 | Evp, Head Of North America | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-11-11 | 20,622 | $6.80 | 27,474 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-11-11 | 28,717 | $24.29 | 56,191 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-11-11 | 11,642 | $30.66 | 67,833 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-11-11 | 38,051 | $65.68 | 29,782 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-11-11 | 17,540 | $66.95 | 12,242 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-11-11 | 11,070 | $67.56 | 1,172 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-11-11 | 200 | $68.43 | 972 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-11-11 | 20,622 | $0.00 | 20,622 | $6.80 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-11-11 | 28,717 | $0.00 | 28,717 | $24.29 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-11-11 | 11,642 | $0.00 | 11,642 | $30.66 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 25,790 | 2032-02-08 | No | 4 | M | Direct | |
| 71,283 | 2030-11-09 | No | 4 | M | Direct | |
| 37,108 | 2031-02-10 | No | 4 | M | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024.
- The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $65.18 to $66.1799 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $66.33 to $67.3299 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $67.33 to $68.3299 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
- The stock options were granted on November 9, 2020. The options are fully vested.
- The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Billionaire Hedge Funds
